Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus Aloe vera in untreatable advanced solid neoplasms

被引:31
|
作者
Lissoni, P
Giani, L
Zerbini, S
Trabattoni, P
Rovelli, F
机构
[1] Osped San Gerardo, Div Surg 2, I-20052 Milan, Italy
[2] Osped San Gerardo, Div Radiat Oncol, I-20052 Milan, Italy
关键词
Aloe vera; biotherapy; melatonin; natural cancer therapy; pineal gland;
D O I
10.1159/000069427
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology. Either cytokines such as IL-2, or neurohormones, such as the pineal indole melatonin (MLT), may activate anticancer immunity. In addition, immunomodulating substances have also been isolated from plants, particularly from Aloe vera. Preliminary clinical studies had already shown that MLT may induce some benefits in untreatable metastatic solid tumor patients, whereas, for the time being, no clinical trial has been performed with aloe products. We have carried out a clinical study to evaluate whether the concomitant administration of aloe may enhance the therapeutic results of MLT in patients with advanced solid tumors for whom no effective standard anticancer therapies are available. The study included 50 patients suffering from lung cancer, gastrointestinal tract tumors, breast cancer or brain glioblastoma, who were treated with MLT alone (20 mg/day orally in the dark period) or MLT plus A. vera tincture (1 mi twice/day). A partial response (PR) was achieved in 2/24 patients treated with MLT plus aloe and in none of the patients treated with MLT alone. Stable disease (SD) was achieved in 12/24 and in 7/26 patients treated with MLT plus aloe or MLT alone, respectively. Therefore, the percentage of nonprogressing patients (PR + SD) was significantly higher in the group treated with MLT plus aloe than in the MLT group(14/24 vs. 7/26, p < 0.05). The percent 1-year survival was significantly higher in patients treated with MLT plus aloe (9/24 vs. 4/26, p < 0.05). Both treatments were well tolerated. This preliminary study would suggest that natural cancer therapy with MLT plus A. vera extracts may produce some therapeutic benefits, at least in terms of stabilization of disease and survival, in patients with advanced solid tumors, for whom no other standard effective therapy is available.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 19 条
  • [1] Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms
    Lissoni, P.
    PATHOLOGIE BIOLOGIE, 2007, 55 (3-4): : 201 - 204
  • [2] A RANDOMIZED STUDY WITH THE PINEAL HORMONE MELATONIN VERSUS SUPPORTIVE CARE ALONE IN PATIENTS WITH BRAIN METASTASES DUE TO SOLID NEOPLASMS
    LISSONI, P
    BARNI, S
    ARDIZZOIA, A
    TANCINI, G
    CONTI, A
    MAESTRONI, G
    CANCER, 1994, 73 (03) : 699 - 701
  • [3] A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies
    Lissoni, P
    Bolis, S
    Brivio, F
    Fumagalli, L
    ANTICANCER RESEARCH, 2000, 20 (3B) : 2103 - 2105
  • [4] Psychoneuroendocrine Modulation of Regulatory T Lymphocyte System: In Vivo and In Vitro Effects of the Pineal Immunomodulating Hormone Melatonin
    Vigore, Luigi
    Messina, Giusy
    Brivio, Fernando
    Fumagalli, Luca
    Rovelli, Franco
    Di Fede, Giuseppe
    Lissoni, Paolo
    IN VIVO, 2010, 24 (05): : 787 - 789
  • [5] Synchronization of Cortisol Circadian Rhythm by the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients and its Possibile Prognostic Significance on Tumor Progression
    Brivio, Fernando
    Fumagalli, Luca
    Fumagalli, Gabriele
    Pescia, Simonetta
    Brivio, Rinaldo
    Di Fede, Giuseppe
    Rovelli, Franco
    Lissoni, Paolo
    IN VIVO, 2010, 24 (02): : 239 - 241
  • [6] CLINICAL-RESULTS WITH THE PINEAL HORMONE MELATONIN IN ADVANCED CANCER RESISTANT TO STANDARD ANTITUMOR THERAPIES
    LISSONI, P
    BARNI, S
    CATTANEO, G
    TANCINI, G
    ESPOSTI, G
    ESPOSTI, D
    FRASCHINI, F
    ONCOLOGY, 1991, 48 (06) : 448 - 450
  • [7] Neuroimmunomodulation in medical oncology:: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors
    Lissoni, Paolo
    Brivio, Fernando
    Fumagalli, Luca
    Messina, Giusy
    Vigore, Luigi
    Parolini, Daniela
    Colciago, Massimo
    Rovelli, Franco
    ANTICANCER RESEARCH, 2008, 28 (2B) : 1377 - 1381
  • [8] EFFICACY AND TOLERABILITY OF CANCER NEUROIMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 AND THE PINEAL HORMONE MELATONIN - A PROGRESS REPORT OF 200 PATIENTS WITH ADVANCED SOLID NEOPLASMS
    LISSONI, P
    ARDIZZOIA, A
    BARNI, S
    BRIVIO, F
    TISI, E
    ROVELLI, F
    TANCINI, G
    MAESTRONI, G
    FUMAGALLI, L
    ONCOLOGY REPORTS, 1995, 2 (06) : 1063 - 1068
  • [9] Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone
    Lissoni, P
    Cazzaniga, M
    Tancini, G
    Scardino, E
    Musci, R
    Barni, S
    Maffezzini, M
    Meroni, T
    Rocco, F
    Conti, A
    Maestroni, G
    EUROPEAN UROLOGY, 1997, 31 (02) : 178 - 181
  • [10] Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status
    Lissoni, P
    Barni, S
    Mandalà, M
    Ardizzoia, A
    Paolorossi, F
    Vaghi, M
    Longarini, R
    Malugani, F
    Tancini, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (12) : 1688 - 1692